Meet us at the DGK Conference 2024 in Mannheim
Venus Medtech is committed to structural heart innovation. Our exceptional heart valve solutions target all four heart valves.
Be sure to join our symposium at DGK 2024 Mannheim 2024, Tricuspid Transcatheter Valve Replacement: How to Keep Things in Motion on April 5th, 17:30 at Hall 17. Scroll down to learn more.
Venus Medtech is committed to structural heart innovation. Our exceptional heart valve solutions target all four heart valves.
Be sure to join our symposium at DGK 2024, Tricuspid Transcatheter Valve Replacement: How to Keep Things in Motion on April 5th, 17:30 at Hall 17. Scroll down to learn more.
Attend the session to learn the latest about about structural heart intervention
You are welcome to listen to top investigators at the Deutsche Gesellschaft für Kardiologie who will discuss the latest results and future plans for the Venus Medtech’s solutions for structural heart disease.
Venus Medtech and Cardiovalve Symposium.
Tricuspid Transcatheter Valve Replacement:
How to Keep Things in Motion.
Friday, April 5th 17:30 – 19:00 h
Location: Hall 17.
Chairman:
Prof Georg Nickenig
Prof Stephan Baldus
17:30
Session objectives
Prof. Georg Nickenig & Prof. Stephan Baldus
17:35
TR patients Comorbidities, natural history, and quality of life
Dr. Christian Besler
17:50
The landscape of Transcatheter Tricuspid valve interventions
Prof. Philipp. Lurtz
18:05
TARGET Study: latest clinical updates
Dr. Christian Frerker
18:20
Advanced imaging: Preliminary echo findings from the TARGET study
Dr. Nina Wunderlich
18:35
Live in a box: Transcatheter Tricuspid Valve Replacement
Dr. Marcel Weber
18:50
Session evaluation and Q&A
Learn more about SMART-ALIGN Multicenter Study
Learn more about the SMART-ALIGN study below.
Multi-center Study
The SMART-ALIGN Study
The objective of the SMART-ALIGN Study is to evaluate the safety, effectiveness, and performance of the Venus-Vitae Transcatheter Heart Valve System in patients with severe aortic stenosis.
150 participants
A total of 150 subjects will be enrolled.
20 Medical Center
Centers will be located in North America and Asia
Endpunkte
All-cause mortality at 1 year; Primary Effectiveness: Acceptable bioprosthesis function at 30 days by echocardiogram (Mean gradient < 20mmHg and Less than moderate aortic regurgitation).
Becoming a Leader
in Structural Heart Disease